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Working out diagnostic and therapeutic algo‑
rithms in medicine is becoming essential on ac‑
count of that it increases knowledge originating 
from a considerable number of published reports 
on clinical trials. The simplicity of such algorithms 
enables their wide application in everyday medi‑
cal practice. The algorithms may have limitations 
mainly due to simplifications, which not always 
turn out to be useful in solving complex clini‑
cal problems of an individual patient. To serve 
as “signpost” in clinical practice, the scheme ought 
to be worked out strictly according to the appro‑
priately inter preted data originating from re‑
liable, current and published medical informa‑
tion. This aim is accomplished by clinical prac‑
tice guidelines, being worked out by scientific 
societies. It should be emphasized that the algo‑
rithms presented in such guidelines need to be 
one of the components taken into account dur‑
ing clinical decisions, and their application should 
consider individual assessment of a clinical situa‑
tion. It is also worth mentioning that the guide‑
lines are prepared mainly based on data coming 
from large, randomized controlled trials. The na‑
ture of those trials, and, in particular, a selective 
choice of patients, limits their approach towards 
some groups of patients, particularly the elder‑
ly, patients with serious concomitant diseases 
and multiple risk factors, and females. These are 
the patients, who are often not enrolled in ran‑
domized clinical trials. Those limitations result‑
ing from inter pretation of clinical trials should be 
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 3) Class III * – there is scientific evidence or gen‑
eral agreement that a method of treatment 
is useless/ineffective, and sometimes may be 
harmful.
Gradation of scientific evidence 
 1) Level A – data derived from multiple random‑
ized clinical trials or from meta‑analyses.
 2) Level B – data derived from a single random‑
ized clinical trial or several large non‑ran‑
domized trials.
 3) Level C – concurrent opinion of experts 
and(or) results of small studies; data from 
retrospective studies and registers.
diagnostic algorithms in CHF Diagnosis of CHF is 
first of all clinical made based on subjective and 
objective symptoms. Properly selected tests help 
confirm the diagnosis, although it should be em‑
phasized that a single, specific test enabling heart 
failure diagnosis is not available.
A definition of heart failure, according 
to the guidelines of the ESC, underlines the ne‑
cessity of existence of:4
 1) symptoms of heart failure (at rest or with ex‑
ertion) and
 2) objective (preferably echocardiographic) in‑
dications of cardiac dysfunction (systolic 
and[or] diastolic) at rest 
 3) and, in case of diagnostic doubts, positive re‑
sponse to treatment directed towards heart 
failure (HF).
Criteria 1 and 2 have to be fulfilled at all 
events.
Based on such a definition, an appropriate 
scheme for proper diagnosis of heart failure can 
be produced (FIGuRE 1). Interpretation of the symp‑
toms mentioned above in clinical practice may be 
difficult and it requires taking the patient’s age, 
sex, obesity and concomitant diseases into con‑
sideration. It is also well known that the relation‑
ship between in symptoms of heart failure and 
the degree of cardiac dysfunction is weak, and 
long‑term prognosis depends mainly on the mag‑
nitude of an increase in symptoms.4 All guidelines 
for clinical practice recommend that the classifi‑
cation of the stages of heart failure should be ap‑
plied according to the NYHA (TABLE 1).
The rest ECG and the chest X‑ray should 
constitute essential components of initial di‑
agnostics of heart failure (FIGuRE 1). A helpful 
test, which in the case of correct results virtu‑
ally enables ruling out heart failure, is the as‑
sessment of the B‑type natriuretic peptide (BNP, 
NT‑proBNP) level.1,4 This test could be particu‑
larly useful in primary health care and in hospital 
emergency units. Other laboratory tests, which 
are used in initial assessment of a patient being 
diagnosed for chronic heart failure, include com‑
plete blood count, levels of electrolytes, creatinine, 
glucose, liver enzymes, thyroid hormones in se‑
rum and a routine urine analysis.1,4
Echocardiography is a method of choice to con‑
firm systolic or diastolic heart dysfunction. 
particularly considered in the population of Polish 
patients with heart failure, especially as they may 
overlap with limited following the doctor’s rec‑
ommendations. Individual conditions of the pa‑
tients, including their financial situation and high 
prices they pay for complex pharmacotherapy, in‑
fluence the way Polish patients follow the rules 
of long‑time therapy in heart failure. Attention 
should be paid to the fact that the effectiveness 
of treatment in heart failure is associated with 
not only of properly applied therapeutic strat‑
egies, but also a patient’s appropriate behavior 
and cooperation.
Within the field of treatment for chronic heart 
failure (CHF) there are four main sets of guide‑
lines developed by:
 1) European Society of Cardiology (ESC) 
of 20051
 2) American College of Cardiology/American 
Heart Association (ACC/AHA) of 20052
 3) Heart Failure Society Of America (HFSA) 
of 20063
 4) Canadian Cardiovascular Society (CCS) of 2006 
(updated in 2007).4
As the Polish Cardiac Society recommended im‑
plementation of the European guidelines in Po‑
land, the diagnostic and therapeutic algorithms 
presented below are compliant with those guide‑
lines. The existing differences between the men‑
tioned recommendations are included in the com‑
mentaries (titled “Comparison between the 
guidelines...”).
Guidelines for scientific societies have been 
divided into recommendation classes, consid‑
ering the level of scientific evidence supporting 
the recommendations.
Recommendation classes 
 1) Class I – there is scientific evidence and(or) 
general agreement that the analyzed diagnos‑
tic procedure/method of treatment is bene‑
ficial, useful and effective.
 2) Class II – data from studies are ambiguous 
and(or) there exist divergent opinions con‑
cerning the usefulness/effectiveness of a giv‑
en form of therapy.
 a) Class IIa – evidence/opinions confirming 
the usefulness/effectiveness of a method 
predominate.
 b) Class IIb – evidence/opinions do not suffi‑
ciently confirm the usefulness/effective‑











* European Society 
of Cardiology advise 
not to apply procedures 
included in class III
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Confirmation of that dysfunction by echocar‑
diography or other imaging methods (cardiac 
magnetic resonance, radioisotope tests) is nec‑
essary to diagnose HF.1‑4
Invasive tests (coronary angiography, right 
heart catheterization with hemo dynamic mea‑
surements, endomyocardial bio psy) are not rou‑
tine tests essential for diagnosis of chronic HF.1 
However, in selected clinical situations, they may 
be helpful in determining a cause of the disease 
and introducing appropriate therapy.1
Treatment algorithm in CHF Treatment in heart 
failure aims at: preventing the progress of patho‑
physio logical lesions in the cardiovascular system 
associated with neurohormone activation, de‑
creasing the intensity of complaints, improving 
the quality of life and increasing survival rates.
Therapy in patients with CHF due to systolic 
dysfunction involves non‑pharmaco logical mea‑
sures (guidelines for lifestyle), drug therapy, im‑
planting cardioverter‑defibrillators and(or) re‑
synchronization device, mechanical support and 
surgical treatment. The proposed guidelines for 
graded non‑pharmaco logical, pharmaco logical 
and surgical treatment for CHF are presented 
in FIGuRE 2.
Pharmacotherapy Angiotensin‑converting enzyme 
inhibitors (ACEI) ACEI treatment is a cornerstone 
of heart failure therapy in order to reduce morbid‑
ity and mortality. The ACEI therapy should be ini‑
tiated from class I according to the NYHA. There 
are several studies related to the role of ACEI 
in patients with symptomatic chronic heart fail‑
ure (Cooperative North Scandinavian Enalapril 
Survival Study, Vasodilator‑Heart Failure Tri‑
al II and Studies of Left Ventricular Dysfunc‑
tion – with enalapril) and in patients after myo‑
cardial infarction (Survival and Ventricular En‑
largement trial – with captopril, Acute Infarction 
Ramipril Efficacy Study – with ramipril, Trandol‑
april Cardiac Evaluation Study – with trandola‑
pril). Based on those studies, it has been found 
that convertase inhibitors reduce mortality risk 
in CHF by 16%.1
Thus the following recommendations have been 
developed.1
Class I, level A. ACEI should be used in all patients 
with reduced left ventricular ejection fraction (LVEF), 
on condition that there are no contraindications and 
tolerance is good.
The role of appropriate dosing ACEI, particu‑
larly before starting a therapy with other groups 
of medications, is being emphasized. The Assess‑






































































β‑adrenolytics β‑adrenolytic therapy should be 
started in CHF patients in NYHA class II, or in pa‑
tients after myocardial infarction from class I.
Clinical trials involving β‑adrenolytics in CHF 
do not show the class effect. Studies, like the Heart 
failure Bisoprolol Study II (CIBIS II; with biso‑
prolol), the Metoprolol CR/XL Randomized Inter‑
vention Trial in Congestive Heart Failure (with ex‑
tended release metoprolol succinate), the Carve‑
dilol Prospective Randomized Cumulative Sur‑
vival Trial (with carvedilol) and the Study of Ef‑
fects of Nebivolol Intervention on Outcomes and 
Rehospitalisation in Seniors with heart failure 
(with nebivolol) showed effectiveness in reduc‑
ing morbidity and mortality in CHF patients.1 
On the other hand, trials involving bucindolol 
(Beta‑Blocker Evaluation of Surviv al Trial) and 
short‑acting metoprolol (Metoprolol in Dilated 
Cardiomyopathy Study) did not show beneficial 
effects of those medications.1,2
Thus the following recommendation has been 
framed.1
Class I, level A. β‑adrenolytics (bisoprolol, carve‑
dilol, extended release metoprolol succinate and 
nebivolol) should be used, if no contraindications, 
in all patients with stable heart failure (in NYHA 
classes II–IV).
Observations have shown that higher dos‑
es of β‑adrenolytics offer greater clinical bene‑
fits. In the Heart failure Bisoprolol Study I study, 
a 5 mg bisoprolol dose was used and slight im‑
provement, which was not statistically signifi‑
cant, was achieved. Only after the administration 
of a 10 mg bisoprolol dose in the CIBIS II study, 
a significant reduction in mortality was showed. 
However, it should be remembered that reaching 
the target dose ought to be slow and individual‑
ized, and depended on a patient’s response. Treat‑
ment should be started in patients, who do not 
display symptoms of hypervolemia, or such symp‑
toms are barely detectabable. Usually, the admin‑
istration is initiated from quite small doses, which 
are then gradually increased.1,2,4
study showed that although treatment with large 
doses of lisinopril failed to reduce total mortali‑
ty as compared to small doses of the medication, 
it reduced the frequency of hospitalization due 
to exacerbated heart failure.1,5 Therefore, the ACEI 
therapy should not be limited only to achieving 
symptomatic improvement. However, if it is ap‑
propriate to use other medications (particularly 
β‑adrenolytics), the ACEI treatment should be in‑
tensified (up to a target dose) only after the in‑
troduction of such medications.
Class I, level A. Doses of ACEI should be gradu‑
ally increased to achieve the dosage of effectiveness 
showed in large controlled clinical trials.
The European guidelines provide a list of ACEI, 
whose effectiveness has been shown in large con‑
trolled clinical trials on HF or left ventricular 
dysfunction. These medications, whose impact 
on mortality/frequency of hospitalization in CHF 
is documented, include:1
 1) captopril (target dose: 25–50 mg 3 times 
daily)
 2) enalapril (target dose: 10 mg twice daily)
 3) lisinopril (target dose: 5–20 mg twice daily)
 4) ramipril (target dose: 2.5–5 mg twice daily)
 5) trandolapril (target dose: 4 mg once daily)
Comparison between the European and American and 
Canadian guidelines The guidelines are fully unan‑
imous that ACEI constitute a basis for heart fail‑
ure treatment. The Canadian guidelines, like‑
wise the European ones, list particular medica‑
tions of that group and their dosage whose ef‑
fectiveness has been showed in large random‑
ized controlled clinical trials with hard outcomes. 
The Canadian guidelines clearly prefer and rec‑
ommend precisely those medications (class I, lev‑
el A).4 Slight differences pertain among others 
to the recommended dosage of lisinopril once 
daily. The ACC/AHA guidelines provide the wider 
spectrum of medications used in CHF treatment. 
They also take fosinopril, perindopril and chi‑
napril into consideration.2 The HFSA guidelines 
do not specify medications or their dosage.
TABLE 2  Effectiveness of ARB in comparison with ACEI in large randomized controlled clinical trials with hard outcomes





















β‑adrenolytics 16%/23% 79% 70% 35% 55%
Cardiovascular mortality no difference favors captopril  no difference no difference favors candesartan, 
favors both 
agents 
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of aldosterone receptor antagonists in class I rec‑
ommendations with the B level of evidence, 
the HFSA recommendations assign class I and 
the A level of evidence to that indication. It is 
associated with the fact that the HFSA, in their 
assessment of the level of evidence, took the re‑
sults of the Eplerenone Post‑Acute Myocardi‑
al Infarction Heart Failure Efficacy and Surviv‑
al Study into account.3 This study showed favor‑
able effects of eplerenone in patients early af‑
ter acute myocardial infarction, with low LVEF 
(≤40%) and heart failure or diabetes.3 The Cana‑
dian guidelines additionally recommend the use 
of those medications only in patients with LVEF 
below 30%.4
Angiotensin receptor blockers (ARB) It is well 
known that in patients with symptomatic CHF 
despite the ACEI treatment, the level of angio‑
tensin II increases. Responsible for this pheno‑
menon are additional enzymatic path ways (e.g. 
associated with chymase), where angiotensin II 
is produced. It provides theoretical rationale for 
the use of ARB, also combined with ACEI. The re‑
sults of clinical studies that compared the effec‑
tiveness of ACEI and ARB were, however, ambi‑
guous (TABLE 2).
It was a basis for the following recommenda‑
tions.1
Class I, level B. In patients with heart failure symp‑
toms, ARB may be used instead of ACEI, in case of in‑
tolerance. Such treatment reduces mortality and 
morbidity.
Class IIa, level B. ARB and ACEI seem to be 
equally effective in the reduction of mortality and 
morbidity.
Class I, level B. Impact of medications from both 
groups on mortality in the course of acute myocardial 
infarction with symptoms of heart failure or left ven‑
tricular dysfunction is similar or the same.
Class IIa, level B. ARB and ACEI combined thera‑
py may be considered, if, despite the use of one med‑
ication, clinical symptoms persist. This therapy re‑
duces mortality.
Class I, level A. Such treatment also reduces 
the risk of hospitalization due to heart failure.
Comparison  between  the  European  and  Ameri‑
can and Canadian guidelines In respect of use 
of β‑adrenolytics in CHF, the recommendations 
are generally unanimous. The Canadian guide‑
lines extend only a scope of use of those medica‑
tions to all patients with LVEF ≤40%, irrespective 
of the NYHA class.4 The ACC/AHA and the CCS 
guidelines recommend bisoprolol, carvedilol, ex‑
tended release metoprolol succinate (the Europe‑
an guidelines also recommend nebivolol).
Aldosterone receptor antagonists The Random‑
ized Aldactone Evaluation Study showed that 
in patients with advanced CHF (NYHA III–IV) and 
LVEF ≤35%, adding spironolactone to the ACEI 
treatment with a diuretic and digoxin (most pa‑
tients) significantly reduces mortality.2,4 Only 
10% of patients involved in that study were ad‑
ministered β‑adrenolytics.2,4
The following recommendation has been 
issued.1
Class I, level B. It is recommended to use al‑
dosterone receptor antagonists along with ACEI, 
β‑adrenolytics and diuretics in patients with ad‑
vanced CHF (NYHA III–IV) due to left ventricular 
systolic dysfunction (LVSD), because it reduces mor‑
tality and morbidity in those patients.
The treatment mentioned above should be 
provided only in patients, in whom it is possible 
to monitor closely the renal function and the se‑
rum potassium level. The medications recom‑
mended in the guidelines are spironolactone and 
eplerenon in a target dosage of 50 mg daily.1,2,4 
A large recommended target dose of spironolac‑
tone is worth mentioning, in particular with other 
medications having an effect on the renin‑angio‑
tensin system (RAS). It is notable that in the Ran‑
domized Aldactone Evaluation Study, a mean daily 
dose of spironolactone was 26 mg.6 The research‑
ers emphasized in their commentary that severe 
hyperkalemia had most frequently occurred in pa‑
tients receiving 50 mg of spironolactone daily.6
Comparison between the European and American and 
Canadian guidelines As opposed to the Europe‑
an, Canadian and ACC/AHA guidelines, which 







































guidelines introduce a new approach: determina‑
tion of the recommendation class and recommen‑
dation level depending on the anticipated clinical 
effect.1 It is closely related to the results of clini‑
cal trials. Since a reduction in the hospitalization 
frequency in CHF, as a result of ACEI + ARB com‑
bined treatment was observed in two large clinical 
trials (CHARM‑Added and Val‑HeFT)7,8, this indi‑
cation was assigned class I and the A level of rec‑
ommendations by the ESC1. And because a fa‑
vorable impact on mortality in CHF was shown 
only in the CHARM‑Added trial7,8, this indica‑
tion was assigned a lower level of recommenda‑
tions by the ESC (IIa B)1. The Canadian guide‑
lines generally grant the combination of ACEI 
and ARB in CHF a high level of recommenda‑
tions (I A).4 The commentary states it pertains 
to a reduction in the hospitalization frequency.4 
The American guidelines also do not diversify out‑
comes and anticipated clinical effects. The HFSA 
guidelines do not generally differ from the Eu‑
ropean and Canadian guidelines, and the ana‑
lyzed combination has a recommendation level 
of IIa A.3 The ACC/AHA guidelines significantly 
differe from the others and limit the clinical sig‑
nificance of ACEI + ARB combination (recommen‑
dation level IIb B).2
The described differences show how diversified 
could be inter pretations of results of large clin‑
ical trials carried out according to the evidence‑
‑based medicine (EBM) rules.
Cardiac glycosides
Class I, level B. Cardiac glycosides are recommend‑
ed in atrial fibrillation and symptomatic heart fail‑
ure of any degree.
Class IIa, level A. Digoxin may reduce the frequen‑
cy of hospitalization due to CHF in patients with pre‑
served sinus rhythm and decreased LVEF.
The recent re‑analysis of the DIG trial has 
shown that in subjects with low plasma digox‑
in levels (0.5–0.9 ng/ml) not only a reduction 
in the frequency of hospitalization, but also a sig‑
nificant reduction in mortality can be observed.9 
The administered digoxin doses should probably 
be reduced to ≤0.125 mg daily.9
Comparison between the European and American and 
Canadian guidelines The European and Canadian 
guidelines list ACEI whose effectiveness has been 
shown in large controlled clinical trials on heart 
failure or left ventricular dysfunction. Medica‑
tions of this group, which in this indication has 
documented an impact on mortality/hospitaliza‑
tion frequency comprise as follows:1,4
 1) candesartan (target dose: 32 mg)
 2) valsartan (target dose: 320 mg).
The ACC/AHA guidelines additionally mention 
losartan as a medication used in cardiac insuffi‑
ciency with left ventricular systolic dysfunction 
(target dose: 50–100 mg).2
The existing divergences in the results of clin‑
ical trials on heart failure using ARB (TABLE 2) re‑
sulted the guidelines for use of this group of med‑
ications, proposed by the Societies (TABLE 3).
In case of intolerance of ACEI, the existing dif‑
ferences in guidelines of different Societies are few 
and have no practical significance. Significant diver‑
gences appear, however, with the use of ARB in pa‑
tients with maintaining symptoms of heart fail‑
ure, despite appropriate treatment with ACEI and 
β‑adrenolytics. In such cases, the ESC guidelines 
themselves are not coherent in respect of com‑
bined administration of ACEI and ARB and the mo‑
ment of introduction of such therapy in a symp‑
tomatic patient. In chart no 4 in the original text 
of the guidelines (FIGuRE 3 in this paper), adding ARB 
is recommended in patients who, despite the use 
of ACEI and β‑adrenolytics remain in NYHA func‑
tional class III.1 In Table 22 in the original text 
of the guidelines, such combination is acceptable 
already in patients in NYHA class II.1 This ambi‑
guity is probably associated with the results of 2 
large clinical trials which showed the effective‑
ness of such combination: the Valsartan Heart 
Failure Trial (Val‑HeFT) and the Candesartan 
in Heart Failure – Added Trial (CHARM‑Added tri‑
al).7,8 Both trials involved patients in NYHA func‑
tional class II–IV. In the Val‑HeFT trial the major‑
ity were the patients included in NYHA function‑
al class II (62%), and in the CHARM‑Added trial, 
patients in NYHA class III (73%).7,8
Furthermore, in the case of combined 
use of ACEI and ARB in CHF, the European 
TABLE 3  Comparison of guidelines for use of ARB in CHF in different guidelines
ESC ACC/AHA CCS HFSA
Class Level Class Level Class Level Class Level
ACEI intolerance I B I A I A I A
Along with ACEI – – IIb B I A IIa A
Mortality reduction* IIa B – – – – – –
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edema.1 The use of those medications reduces heart 
failure symptoms.
Rules  for  diuretic  use Diuretics, as compared 
to other agents used in CHF, cause the quickest 
symptomatic improvement in patients with signs 
of pulmonary and(or) systemic congestion.2
Appropriate use of diuretics influences the ef‑
fectiveness of therapy with other medications 
in CHF. Too small doses may cause fluid retention, 
reduce a response to ACEI and increase the risk 
of treatment with β‑adrenolytics. In turn, too 
large doses of diuretics may increase the risk 
of hypotonia, when taking ACEI, and renal in‑
sufficiency, when taking ACEI and ARB.2 The ob‑
jective of treatment is a reduction in congestion 
and body weight, usually of 0.5–1 kg daily.2 Nor‑
mally, loop diuretics are recommended as first‑line 
agents.2,4 Furosemide is used most frequently. 
Many patients respond well to a newer loop di‑
uretic, i.e. torsemide, which has better bio logical 
availability and longer effects.2 Thiazide diuretics 
(when glomerular filtration rate >30–40 ml/min), 
potassium‑saving diuretics or their combinations 
may also be used.
Potassium level should be preserved definite‑
ly above 4 mmol/l.4,9,11
After achieving clinical improvement, it is ap‑
propriate to use a diuretic chronically in the small‑
est dose essential to maintain a patient in a stable 
condition.4 Caution is necessary in chronic use 
of diuretics, because to date no results of larger, 
randomized clinical trials assessing the outcomes 
of treatment with this group of medications are 
available. Diuretics may potentially intensify neu‑
rohormone activation, which is increased in CHF. 
The analysis of patients involved in the DIG trial, 
which was made using the propensity score in or‑
der to reduce the influence of disturbing factors, 
showed that the CHF patients treated with a di‑
uretic manifested higher total mortality (29% 
Comparison between the European and American and 
Canadian guidelines The existing divergences be‑
tween guidelines concern the use of digoxin in pa‑
tients with preserved sinus rhythm. The HFSA 
recommendations are similar to the Europe‑
an ones.3 The ACC/AHA guidelines are similar, 
and differ only in the assigned lower level of evi‑
dence (B).2 The Canadian guidelines acknowledge 
recommendations class I with the A level of clin‑
ical evidence for this indication.4 The existing 
differences are probably associated with the fact 
that most studies documenting the effectiveness 
of digoxin come from the period, when other med‑
ications (particularly β‑adrenolytics and ARB) 
were used less frequently. They also signify that 
in drawing up the guidelines for clinical practice 
“expert opinions” may be substantial in the assess‑
ment of significance of scientific evidence.10
Hydralazine – isosorbide dinitrate 
Class IIa, level B. In case of intolerance of ACEI 
and ARB and renal insufficiency, an attempt to treat 
with hydralazine/nitrates may be made in order 
to reduce mortality and morbidity and to improve 
the quality of life.
Comparison between the European and American and 
Canadian guidelines The ACC/AHA and Canadian 
guidelines assign for this indication a lower rec‑
ommendation of class IIb and the level of evidence 
B or C.2,4 However, it seems that the available sci‑
entific evidence does not show that in patients not 
tolerating ACEI/ARB, particularly in renal insuf‑
ficiency, the combination of hydralazine and ni‑
trates may bring beneficial clinical effects.10
diuretics 
Class I, level A. Diuretics are a basis for treatment 
mitigating the symptoms in case of hypervolemia 

























































(17% vs. 28%, p <0.001).13 Similar benefits from 
the program of multidisciplinary outpatient clin‑
ic treatment after hospital discharge were shown 
by Wierzchowiecki et al. also in the Polish pop‑
ulation.14 The experience of the attending team 
and frequent control visits in an outpatient clin‑
ic (14 days after hospital discharge and at the 3rd, 
6th, 9th and 12th months) are thought to have 
been significant in achieving such positive results. 
Attention should also be paid to the fact that 
in case of difficult patients (quick, treatment‑re‑
sistant progression of heart failure, suspected in‑
flammatory etiology), particularly during the first 
phase of treatment, a relevant role may be played 
by a consultation provided by a cardio logist spe‑
cializing in CHF treatment, in order to expand 
the diagnostics and tailor therapy to the patient 
needs.
Lack of satisfactory methods of CHF patient 
treatment objective assessment is one of the rea‑
sons for the limited introduction of the present‑
ed guidelines to everyday medical practice.5,15 
The recent Euro Heart Survey on heart failure, 
performed by the ESC, demonstrated that only 
78% of patients with CHF and LVSD were treat‑
ed with ACEI.5 Only 46% of patients were receiv‑
ing β‑adrenolytics, and 29% aldosterone antag‑
onist.5 In that European study involving 10,701 
patients, the doses of administered medications 
were significantly lower than those used in large 
controlled clinical trials.5 Only half of patients 
who met the inclusion criteria in the SOLVD 
study, were receiving a target dose of ACEI, and 
only 10% of patients, who met the criteria for en‑
rollment in the MERIT‑HF study, were receiving 
β‑adrenolytics in a recommended dose.5
An attempt to make the chronic treatment 
of CHF patients more objective is the inclu‑
sion of bio markers, especially BNP/NT‑proBNP, 
in the therapeutic scheme.16 The recently pub‑
lished, multicenter, randomized STARS‑BNP tri‑
al confirmed that the CHF treatment with BNP 
determination may provide greater benefits than 
the therapy based only on clinical symptoms.15 
In a group of patients, where BNP measure‑
ments were additionally used to select the inten‑
sity of pharmaco logical treatment, it was found 
that the use of larger doses of basic medications 
in CHF therapy (up to 106% of doses recommend‑
ed for ACEI and 77% for β‑adrenolytics) is trans‑
lated into less frequent occurence of a combined 
outcome, i.e. deaths and hospitalizations associ‑
ated with CHF (24% in the BNP group and 52% 
in the control group; p <0.001).5 These results are 
promising, but have to be confirmed by studies 
involving more numerous groups of patients and 
based on hard outcomes.
Interventional treatment Cardiac resynchroni‑
zation therapy (CRT) by means of biventricular 
stimulation or biventricular stimulation com‑
bined with cardioverter‑defibrillator.
Class I. Introduction of CRT may be consid‑
ered in patients with lowered LVEF (≤35%), left 
vs. 21%, HR 1.31, p = 0.002) and higher mortal‑
ity due to HF (9% vs. 6% HR 1.36, p = 0.056).11 
These differences were found irrespective of eti‑
ology of heart failure, the NYHA class, ejection 
fraction and ACEI treatment.11 However, it should 
be noted that such retrospective analyses have 
their limitations, because in everyday practice, 
patients requiring diuretics or their large dos‑
es most frequently demonstrate more advanced 
stages of CHF. It may have an effect on higher 
mortality observed in that group.
Selection of a pharmaco logical treatment method 
Based on the analyzed European guidelines, 
we could present a detailed algorithm of phar‑
macotherapy for symptomatic HF caused by left 
ventricular systolic dysfunction (FIGuRE 3).
Selecting a proper dose of medications men‑
tioned in FIGuRE 3, it should be noted that:
 1) In case of ACEI and ARB, the dose should be 
increased gradually up to the recommend‑
ed one, i.e. the dose used in large, random‑
ized, controlled clinical trials with hard out‑
comes. The intended dose must be tolerated 
by a patient.
 2) In patients, in whom the hypervolemia signs 
have been overcome (mainly with ACEI and 
diuretics), β‑adrenolytic therapy should be 
introduced. The dose ought to be increased 
gradually up to the target one, determined 
based on large, controlled clinical trials.
 3) Diuretic dosage should be adjusted individ‑
ually depending on a patient’s clinical condi‑
tion based on intensity of symptoms.
The management of a CHF patient accord‑
ing to the presented algorithms should be 
based on a patient’s thorough history concern‑
ing intensification of symptoms and toleration 
of treatment. It is still an activity involving ele‑
ments of the art of medicine, i.e. subjective as‑
sessment made by an attending physician and 
his/her clinical experience. Taking an appropri‑
ate and in‑depth history of a patient during con‑
trol visits plays a considerable role in the optimi‑
zation of CHF therapy. The role of appropriate‑
ly selected medical teams in chronic care of CHF 
patients should also be emphasized. Apart from 
a cardio logist, such teams need to include a gener‑
al practitioner, a trained nurse, a clinical psycho‑
logist and a physiotherapist. The role of a nurse 
in this system of multidisciplinary care is cru‑
cial. The Argentinean DIAL study showed that 
in CHF patients randomized to a group, where 
a routine care was expanded by telephone con‑
trol of clinical condition, training and modifica‑
tions in treatment of dehydration carried out 
by a trained nurse, a 29% reduction in need for 
hospitalization due to heart failure (p <0.005) was 
observed.12 In their findings, Ezekowitz et al. em‑
phasized the role of a cardio logist in chronic care 
of a CHF patient. In patients who, after hospital 
discharge, were cared for by a general practitio‑
ner and a cardio logist, mortality was lower than 
in patients attended only by a general practitioner 
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are anticipated to survive in a good functional 
condition for over one year.1,20
Primary prevention
Class I, level A (to reduce mortality). In selected 
patients with LVEF ≤30–40% who are of II or III 
NYHA class, on condition that they already under‑
go optimum pharmacotherapy and are anticipated 
to survive in a good functional condition for over one 
year, however, not earlier than 40 days after myo‑
cardial infarction.1,20
Class I, level B (to reduce mortality). The implan‑
tation of ICD is recommended in patients with heart 
disease of etiology other than ischemic, with LVEF 
≤30–35%, being of II or III NYHA class, undergoing 
optimum chronic pharmaco logical treatment and 
with anticipated survival in a good functional condi‑
tion for over 1 year.20
Class IIa, level B (to reduce mortality). The implan‑
tation of ICD is justified in patients with impaired 
LV function due to MI from at least 40 days before, 
with LVEF ≤30–35%, being of I NYHA class, who 
undergo optimum pharmacotherapy and are antic‑
ipated to survive in a good functional condition for 
over one year.20
Class IIb, level B (to reduce mortality). The im‑
plantation of ICD is justified in patients with heart 
disease of etiology other than ischemic, with LVEF 
≤30–35%, being of I NYHA class, who undergo opti‑
mum pharmacotherapy and are anticipated to survive 
in a good functional condition for over one year.20
Comparison between the European and Ameri‑
can and Canadian guidelines In primary preven‑
tion of sudden cardiac death (SCD), the American 
and Canadian guidelines consider patients with 
lower LVEF in class I recommendations (<30%).2‑4 
The European guidelines for heart failure and 
the HFSA ones do not diversify left ventricular 
systolic dysfunction in respect of etiology.1,3 The 
European recommendations for the prevention 
of SCD and the ACC/AHA and the CCS for the use 
of ICD in patients with systolic dysfunction of eti‑
ology other than ischemic, are of a lower degree 
(ESC – I B or IIb B, ACC/AHA – I B; CCS – IIa B or 
IIb B in patients with LVEF 31–35%).2,4,20
Heart revascularization and related surgeries All gu‑
idelines for treatment for CHF concur that in case 
of patients with symptoms of angina pectoris it 
is appropriate to consider surgical or percutane‑
ous heart revascularization (class I or IIa and le‑
vels of recommendation A or B).
Revascularization in order to improve myocar‑
dial contractility or achieve a reduction in CHF 
symptoms is not recommended in case of no 
symptoms of angina pectoris (even in the case 
of hibernated myocardium).1
Explicitly recommended surgery in CHF pa‑
tients is excision of the left ventricular aneu‑
rism. It is recommended in patients with a large, 
sectioned off aneurism and signs of heart fail‑
ure (class I, level C).1 Cardiac transplantation is 
also a recommended method of treatment of fi‑
nal stage heart failure, providing the patients 
ventricular hypertrophy*, sinus rhythm and syn‑
chronization disorders (QRS width ≥120 ms), with 
persisting despite optimum pharmaco logical treat‑
ment CHF symptoms (III–IV NYHA class).1,17
Receiving CRT‑P reduces:
 1) clinical symptoms (class I, level A)1,17
 2) frequency of hospitalization (class I, 
level A)1,17
 3) mortality (class I, level A).17
The use of CRT with cardioverter defibrillator 
is an accepted alternative method of treatment 
in such patients, on condition that the expected 
time of their survival in a good functional condi‑
tion exceeds 1 year (class I, level B).17
The meta analysis of studies concerning resyn‑
chronizing therapy (Multisite Stimulation in Car‑
diomyopathy study; Multicenter InSync Random‑
ized Clinical Evaluation Trial; Multisite Stimu‑
lation in Cardiomyopathy Study; Comparison 
of Medical Therapy, Pacing, and Defibrillation 
in Heart Failure Trial; Cardiac Resynchroniza‑
tion‑Heart Failure Trial) confirmed a favorable in‑
fluence of the treatment on advanced heart failure 
outcomes.18 In comparison with optimal pharma‑
cotherapy, after administering resynchronization 
therapy, a reduction was found in total mortality 
by 29% (odds ratio [OR] 0.71, 95% CI 0.57–0.88) 
and in mortality associated with CHF progression 
by 38% (OR, 0.62, 95% CI 0.45–0.84).15
The role of echocardiography in qualifying pa‑
tients for resynchronization therapy is currently 
being investigated, because clinical and ECG cri‑
teria recommended by the guidelines are not al‑
ways sufficient. However, recently published re‑
sults of the PROSPECT study failed to show that 
currently used ECG manifestations of LV systolic 
dyssynchrony were useful in qualifying patients 
for resynchronization therapy.19
Comparison between  the European and American 
and Canadian guidelines The American, Canadi‑
an and European guidelines (for cardiac stimu‑
lation and resynchronization) provided the de‑
tailed value of LVEF (≤35%), for which the in‑
troduction of resynchronization therapy is rec‑
ommended and assign this form of CHF treat‑
ment with the similar class of recommendation 
(only the HFSA with class IIa).1‑4,17 They, howev‑
er, do not diversify the anticipated clinical effects 
and recognize the A level of evidence for this in‑
dication. It seems to be justified, especially af‑




Class I, level A (to reduce mortality). The implan‑
tation of ICD is recommended in patients who 
survived circulatory arrest caused by ventricular 
fibrillation, and in patients with poorly hemo‑
dynamically tolerated ventricular tachycardia (VT) 
who undergo optimum pharmacotherapy and 
* during the research 
of CRT, different left 
ventricular (LV) widening 
criteria were applied: LV 
end diastolic dimension 
>55 mm, LV end systolic 
dimension >30 mm/m2, 
LV end systolic dimension 
>30 mm/m of height
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 7) avoidance of calcium antagonists (except for 
amlodipine) (class I, level C)1
 8) using class I antiarrhythmic agents is con‑
traindicated, because they increase mortali‑
ty in CHF patients (class III, level B); the med‑
ication of choice (except for β‑adrenolytics) 
is amiodarone, which is effective in control‑
ling most of supraventricular and ventricu‑
lar arrhythmias (class I, level A)
 9) after implanting ICD, it is recommended 
to use amiodarone, sotalol and(or) other 
β‑adrenolytics as a method of pharmaco‑
logical supplementation to ICD therapy 
to mitigate symptomatic ventricular tach‑
yarrhythmias in HF patients receiving opti‑
mal pharmacotherapy (class I, level C)20
 10) routine use of the combination of ACEI, ARB 
and spironolactone is not recommended due 
to an increased risk of hyperkalemia (class III, 
level C)2
 11) influenza vaccination – yearly (class I, lev‑
el B)21, pneumococcal pneumonia vaccina‑
tion – every 6 years (class I, level C).4 
Heart failure with preserved left ventricular ejec‑
tion fraction Heart failure with preserved left 
ventricular ejection fraction (LVEF >40%) is a vi‑
tal clinical issue. Approximately 40–50% of pa‑
tients with CHF symptoms have a preserved left 
ventricular ejection fraction.4 Heart failure with 
preserved left ventricular ejection fraction is not 
identical with heart failure caused by diastolic 
dysfunction.1 Diagnosis of heart failure with pre‑
served left ventricular ejection fraction does not 
indicate that characteristics of left ventricular di‑
astolic dysfunction were found.1 The latter could 
be difficult, particularly in patients with atrial 
fibrillation.1
Hints on treatment of heart failure with pre‑
served left ventricular ejection fraction com‑
ing from clinical or follow‑up studies are scarce. 
Therefore, in the European guidelines we can find 
the following statement: “There is no unambig‑
uous evidence demonstrating that patients with 
initially diastolic heart failure benefit from taking 
individual medications in any way”.1 The Amer‑
ican and Canadian guidelines are more detailed 
in their approach to the methods of treatment 
of CHF patients with preserved LVSF.2,4 They 
are presented in TABLE 4 and they conform with 
the more general European recommendations.
The paper presents a proposal of the diagnostic 
and therapeutic scheme in chronic heart failure, 
worked out based on current guidelines of scien‑
tific societies, to be applied in clinical practice. It 
should be noted that the schemes require period‑
ical updating, because progress in medical knowl‑
edge in the field of heart failure is continuous and 
leads to consistent amendments to the guide‑
lines themselves.
are properly qualified to the surgery (class I, 
level C).1
Surgical corrections of serious functional mi‑
tral regurgitation in patients with advanced LVSD 
in order to reduce the CHF symptoms are promis‑
ing, although they still have a relatively low level 
of recommendation (class IIb, level C).1
Selected other recommendations to the scheme of treat‑
ment resulting from the guidelines1‑4
 1) exercise in a stable period and the routine con‑
duct of training programs (class I, level C)
 2) control of body weight by a patient in respect 
of possible rapid weight gain (class I, level C)
 3) in case of fluid retention: reduction in salt 
supply (usually 2–3 g daily), reduction in fluid 
supply (usually 1.5–2 l daily) (class I, level C)
 4) anticoagulant therapy:
 a) with concomitant atrial fibrillation (class I, 
level A)1
 b) history of thromboembolism (class I, 
level A)1
 c) mobile left ventricular thrombus (class I, 
level A)1
 d) in secondary prevention of coronary heart 
disease it is recommended to administer 
acetylsalicylic acid or oral anticoagulants 
(class IIa, level C)1
 e) chronic use of the combination of antiplate‑
let agents and anticoagulants is not recom‑
mended, except for individual cases (class III, 
level A)4
 5) avoidance of the use of acetylsalicylic acid 
in patients who require frequent hospital‑
ization due to heart failure exacerbation 
(class IIb, level B)1
 6) avoidance of non‑steroid anti‑inflammatory 






























Abbreviations: LVEF – left ventricular ejection fraction, others – see TABLE 2 and 3
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